{"filing":{"accession_number":"0001193125-26-430507","cik":"0001107421","ticker":"TCRT","company_name":"Alaunos Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-22","primary_document":"tcrt-20261022.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526430507/tcrt-20261022.htm"},"events":[{"id":37645,"run_id":34692,"accession_number":"0001193125-26-430507","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The disclosure centers on Alaunos' delisting status from Nasdaq. The Company received a delisting notice on October 5, 2026 for non-compliance with the Stockholders' Equity Requirement (minimum $2.5M), timely requested a hearing, but then regained compliance following a private placement on October 14, 2026. Nasdaq confirmed compliance on October 22, 2026, cancelling the delisting hearing and allowing continued listing. This is a material resolution of a delisting risk that directly affects the registrant's continued trading status.","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42425,"accession_number":"0001193125-26-430507","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on Alaunos' delisting status from Nasdaq. The Company received a delisting notice on October 5, 2026 for non-compliance with the Stockholders' Equity Requirement (minimum $2.5M), timely requested a hearing, but then regained compliance following a private placement on October 14, 2026. Nasdaq confirmed compliance on October 22, 2026, cancelling the delisting hearing and allowing continued listing. This is a material resolution of a delisting risk that directly affects the registrant's continued trading status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:31:40.642081+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42425,"accession_number":"0001193125-26-430507","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on Alaunos' delisting status from Nasdaq. The Company received a delisting notice on October 5, 2026 for non-compliance with the Stockholders' Equity Requirement (minimum $2.5M), timely requested a hearing, but then regained compliance following a private placement on October 14, 2026. Nasdaq confirmed compliance on October 22, 2026, cancelling the delisting hearing and allowing continued listing. This is a material resolution of a delisting risk that directly affects the registrant's continued trading status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:31:40.642081+00:00","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-10-23"}]}